Brussels, 14/10/2015 (Agence Europe) - In a policy orientation document published on Wednesday 14 October, sickness insurance bodies said that pharmaceutical innovation should first and foremost benefit patients whilst contributing to sustainability and universal healthcare.
Given that prices of new medicines have spiralled, the European Social Insurance Platform (ESIP) and the International Association of Mutuals and Health Insurance Funds (AIM) are sounding the alarm and have formulated...